EGFR and non-small cell lung carcinoma: Based on the results of three clinical trials, LUX‐Lung 2, LUX‐Lung 3, and LUX‐Lung 6, afatinib showed better ORR (approximately 70%) and prolonged the PFS (approximately 1 year) in advanced NSCLC patients with EGFR mutations compared with platinum‐based chemotherapy.57, 58, 59